Indap capsules 2.5 mg. №30

Description

Indap Composition
active substance: indapamide;

1 capsule contains 2.5 mg of indapamide;

excipients: lactose, microcrystalline cellulose, corn starch, magnesium stearate, colloidal silicon dioxide;

capsule composition: gelatin, titanium dioxide (E 171), indigo (E 132).

Indap Dosage form
Capsules.

Basic physical and chemical properties: hard gelatin capsules of size No. 4, the cap of the capsule is blue, the body is white, the contents of the capsules are white powder.

Indap Pharmacotherapeutic group
Non-thiazide diuretics with moderate diuretic activity. Sulfonamides, simple. ATX code C03B A11.

Pharmacodynamics
Indapamide is a sulfonamide diuretic that is pharmacologically related to thiazide diuretics. Indapamide inhibits sodium reabsorption in the cortical segment of the kidney. This increases the excretion of sodium and chloride in the urine and, to a lesser extent, the excretion of potassium and magnesium, thus increasing urine output. The antihypertensive effect of indapamide is manifested at doses at which the diuretic effect is negligible. Moreover, its antihypertensive effect persists even in hypertensive patients on hemodialysis.

Indapamide acts at the vascular level by:

a decrease in the contractility of vascular smooth muscles, which is associated with changes in the transmembrane exchange of ions (mainly calcium);
stimulation of the synthesis of prostaglandins PGE2 and prostacyclin PGI2 (vasodilator and inhibitor of platelet aggregation).
Indapamide reduces left ventricular hypertrophy.

Moreover, as shown by studies of various durations (short, medium and long) with the participation of patients with arterial hypertension, indapamide:

does not affect the metabolism of lipids: triglycerides, low density lipoprotein cholesterol and high density lipoprotein cholesterol;
does not affect the metabolism of carbohydrates, even in patients with arterial hypertension and diabetes mellitus.
When the recommended dose is exceeded, the therapeutic effect of thiazides and thiazide-like diuretics does not increase, while the number of adverse events increases. If the treatment is not effective enough, it is not recommended to increase the dose.

Pharmacokinetics

Absorption

The bioavailability of indapamide is high – 93%.

The maximum plasma concentration (max) after taking a dose of 2.5 mg is achieved in 1-2 hours.

Distribution

Plasma protein binding is above 75%.

The half-life is 14 to 24 hours (average 18 hours).

During regular administration of the drug, the level of stable concentration in the blood plasma increases compared to the concentration of indapamide after taking a single dose. This level of concentration in blood plasma remains stable for a long time without the occurrence of cumulation.

Withdrawal

Renal clearance is 60-80% of the total clearance.

Indapamide is excreted mainly in the form of metabolites, the proportion of the drug is excreted by the kidneys unchanged, is 5%.

Patients with renal impairment

In patients with renal insufficiency, pharmacokinetic parameters do not change.

Indications
Essential hypertension.

Contraindications
hypersensitivity to indapamide, other sulfonamides or to any auxiliary component of the drug;
severe renal failure;
hepatic encephalopathy or severe liver disease;
hypokalemia.